Investigational drug · Phase 3
VVN461 1.0%
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-infectious Anterior Uveitis, Anterior Uveitis.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "VVN461 1.0%"
First trial start
2023
Nov 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VVN461 1.0%", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-infectious Anterior Uveitis
- Anterior Uveitis
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VVN461 1.0%" as an intervention, largest first.
- A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisPivotal-lookingActive, not recruiting
VivaVision Biotech, IncIndustry
NCT07136805 · 154 participants · Start Nov 25, 2025 · Primary completion Dec 31, 2026
Drug: VVN461 Ophthalmic Solution 1.0%; 1.0% prednisolone acetate · For: Non-infectious Anterior Uveitis
Sites: Chongqing, China; Beijing, China
- Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract SurgeryCompleted
VivaVision Biotech, IncIndustry
NCT06164743 · 91 participants · Start Jan 11, 2024 · Primary completion May 15, 2024
Drug: VVN461 Ophthalmic Solution 1.0%; VVN461 Ophthalmic Solution 0.5% and 1 more · For: Inflammation
Sites: Inglewood, California; Petaluma, California; Rancho Cordova, California · 10 sites in all
VivaVision Biotech, IncIndustry
NCT06679153 · 89 participants · Start Nov 27, 2023 · Primary completion Dec 29, 2024
Drug: VVN461 Ophthalmic Solution 1.0%; VVN461 Ophthalmic Solution 0.5% and 1 more · For: Anterior Uveitis
Sites: Beijing, China
VivaVision Biotech, IncIndustry
NCT06906198 · 30 participants · Start Mar 1, 2023 · Primary completion May 10, 2023
Drug: VVN461 Ophthalmic Solution 1.0%; VVN461 Ophthalmic Solution 0.5% and 2 more · For: Healthy Volunteers
Sites: Wenzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.